{
    "clinical_study": {
        "@rank": "21727", 
        "arm_group": [
            {
                "arm_group_label": "FIAsp", 
                "arm_group_type": "Experimental", 
                "description": "Each subject will be randomly allocated to one of the two treatment sequences consisting of 2 dosing visits"
            }, 
            {
                "arm_group_label": "NovoRapid\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "Each subject will be randomly allocated to one of the two treatment sequences consisting of 2 dosing visits"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Japan. The aim of the trial is to evaluate the pharmacokinetic\n      (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the trial\n      drug on the body) properties of FIAsp (faster-acting insulin aspart) and the currently\n      marketed insulin aspart (NovoRapid\u00ae) in Japanese subjects with type 1 diabetes."
        }, 
        "brief_title": "A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 1"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 1 diabetes mellitus (as diagnosed clinically) for 12 months or longer\n\n          -  Body mass index (BMI) 18.5-28.0 kg/m^2 (both inclusive)\n\n        Exclusion Criteria:\n\n          -  Subject who has donated any blood or plasma in the past month or more than 500 mL\n             within 3 months prior to screening\n\n          -  Smoker (defined as a subject who is smoking at least one cigarette, cigar or pipe\n             daily)\n\n          -  Not able or willing to refrain from smoking and use of nicotine substitute products\n             during the inpatient period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "43", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01934712", 
            "org_study_id": "NN1218-3918", 
            "secondary_id": [
                "U1111-1121-2896", 
                "JapicCTI-132253"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "FIAsp", 
                    "NovoRapid\u00ae"
                ], 
                "description": "Single dose injected subcutaneously (s.c, under the skin)", 
                "intervention_name": "insulin aspart (FIAsp)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "FIAsp", 
                    "NovoRapid\u00ae"
                ], 
                "description": "Single dose injected subcutaneously (s.c, under the skin)", 
                "intervention_name": "insulin aspart", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 28, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Fukuoka", 
                    "country": "Japan", 
                    "zip": "812-0025"
                }
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Area under the serum insulin aspart concentration-time curve", 
            "safety_issue": "No", 
            "time_frame": "From 0-1 hour"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01934712"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the serum insulin aspart concentration-time curve", 
                "safety_issue": "No", 
                "time_frame": "From 0-12 hours"
            }, 
            {
                "measure": "Area under the glucose infusion rate (GIR) curve", 
                "safety_issue": "No", 
                "time_frame": "From 0-1 hour"
            }, 
            {
                "measure": "Area under the glucose infusion rate (GIR) curve", 
                "safety_issue": "No", 
                "time_frame": "From 0-12 hours"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}